MacroGenics, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; filed March 15, 2023. MacroGenics is a clinical-stage biopharmaceutical company focused on antibody-based cancer therapies. MARGENZA is its only marketed U.S. product. TZIELD, developed by MacroGenics and sold to Provention, was approved in November 2022. All amounts below are in U.S. dollars.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Total revenue | $151.9 million | $77.4 million |
| Operating loss | $121.4 million | $202.8 million |
| Net loss | $119.8 million | $202.1 million |
| Net loss per share | $1.95 | $3.37 |
| Cash used in operating activities | $87.0 million | $143.8 million |
- Revenue increased 96%. Collaborative and other agreement revenue was $119.3 million, including a $60 million Provention milestone for TZIELD approval and $30 million of Incyte milestones. Product sales, net, rose 36% to $16.7 million; contract manufacturing revenue was $14.0 million, compared with none in 2021.
- Research and development expense decreased 4% to $207.0 million; selling, general and administrative expense decreased 7% to $58.9 million. Operating and net losses narrowed, but the company remained unprofitable. The filing says MARGENZA revenue is not expected to be sufficient for profitability.
- Cash, cash equivalents and marketable securities totaled $154.3 million at year-end, down from $243.6 million in 2021. Current assets were $222.2 million and current liabilities were $48.6 million. Accounts receivable was $56.2 million, including $45 million due from Provention for the TZIELD milestone.
- The company reported an accumulated deficit of $1.1 billion. No conventional borrowings are identified in the supplied filing text; lease liabilities were $34.8 million, with $70.3 million of undiscounted future minimum lease payments.
- Company-wide profit margins are not a useful indicator of product economics because revenue includes collaboration milestones and manufacturing services. MARGENZA’s reported cost of sales benefited from inventory costs expensed before approval; the filing does not provide a comparable standalone product margin.
Material changes and business developments
- The $60 million TZIELD regulatory milestone was recognized as 2022 revenue; it was payable in four $15 million installments. The first two installments had been received by the filing date, with the remaining two scheduled for June and September 2023.
- In October 2022, Gilead paid MacroGenics a non-refundable $60 million upfront payment under an option and collaboration agreement for MGD024 and potential DART research programs. Only $0.2 million was recognized as 2022 revenue; $59.8 million remained deferred at year-end. Additional potential milestones total up to $1.7 billion, subject to options being exercised and development and commercial success.
- In March 2023, MacroGenics received $100 million from DRI Healthcare for the sale of its single-digit TZIELD royalty. It retained certain milestone interests and a share of royalties above a specified annual threshold. This subsequent transaction was not 2022 revenue.
- R&D spending shifted toward vobra duo and lorigerlimab: vobra duo expense rose to $55.4 million from $31.3 million, and lorigerlimab expense rose to $21.6 million from $13.4 million. Spending fell on margetuximab, flotetuzumab, tebotelimab and retifanlimab.
- MacroGenics announced a workforce reduction of approximately 15% in August 2022 and planned closures of its California site and a smaller Maryland manufacturing site. It extended its headquarters lease through 2035.
Outlook, risks and unusual items
- Management said year-end liquidity, anticipated and potential collaboration payments and product revenue, together with the $100 million received in March 2023 from the TZIELD royalty sale, were expected to fund operations through 2025. This outlook excludes potential spending for late-stage vobra duo development or further expansion of ongoing studies. The company cautions that additional financing may be required and may not be available on acceptable terms.
- Vobra duo’s TAMARACK study moved into Phase 2 in late 2022. In the first quarter of 2023, the company removed the second-ARAT control arm and the Phase 3 portion; it said a clinical update could come in 2024 and potentially support a later Phase 3 study. The timing and outcome remain uncertain.
- MacroGenics planned a randomized Phase 2 study of lorigerlimab plus docetaxel versus docetaxel alone in second-line, chemotherapy-naive mCRPC in the second half of 2023. Preliminary data reported a 25.7% confirmed partial response rate among 35 evaluable patients with measurable disease; the filing emphasizes that these are preliminary clinical results.
- The company discontinued its enoblituzumab Phase 2 SCCHN study in July 2022 after an internal safety review that included seven fatalities potentially associated with hemorrhagic events among 62 treated patients. I-Mab also notified MacroGenics that it intended to terminate its enoblituzumab license.
- Key risks include clinical-trial failure or delay, adverse events, dependence on collaborators and contract manufacturers, competition, limited commercial capabilities, potential need for additional capital, reimbursement and pricing pressures, intellectual-property challenges, and macroeconomic and supply-chain disruption. MARGENZA carries a boxed warning for left ventricular dysfunction and embryo-fetal toxicity.
- Auditors issued an unqualified opinion on the financial statements and on internal control over financial reporting. The audit identified accounting for the Gilead agreement as a critical audit matter because performance-obligation identification and allocation of the upfront payment required significant estimates.
Investor facts to verify
- Confirm collection of the remaining $30 million in Provention milestone installments and the timing and terms of any further TZIELD-related payments following the royalty sale.
- Track cash burn, collaboration receipts and the assumptions underlying management’s stated runway through 2025, particularly if clinical programs expand.
- Monitor TAMARACK’s modified design, enrollment, safety and efficacy updates, and whether results support a subsequent registrational study.
- Assess the durability and full analysis of lorigerlimab’s preliminary clinical results and the status of its planned randomized Phase 2 study.
- Review MARGENZA sales and market uptake, and evaluate whether the workforce reduction and site closures deliver expected savings without impairing operations.